Literature DB >> 7313543

Pregnancy and parturition in a patient with severe Glanzmann's thrombasthenia.

S B Sundqvist, I M Nilsson, L Svanberg, S Cronberg.   

Abstract

A 35-year-old woman with severe Glanzmann's thrombasthenia became pregnant involuntarily. As a late abortion might cause a bleeding as severe as a delivery, legal abortion was not considered indicated. Treatment with ordinary platelet concentrates was not considered since even HLA-matched platelets did not enhance the platelet function, measured as the aggregability of transfused platelets. This inability was thought to indicate that the patient might have developed antibodies against one of the glycoproteins deficient in this disease. A delivery per vaginam was then preferred because of the local compressing effect. Spontaneous delivery occurred at the end of the 42nd week of pregnancy. The patient delivered a boy with transient thrombocytopenia, probably due to maternal antibodies. To stimulate the haemostasis, uterine contracting drugs were used in unusually large doses and for a relatively long period of time. Tranexamic acid was also given. No haemorrhagic complications could he observed during the puerperium.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7313543     DOI: 10.1111/j.1600-0609.1981.tb00467.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  3 in total

1.  Glanzmann's Thrombasthenia Complicating Pregnancy.

Authors:  Chandrakala Magudapathi; Suthanthira Kannan
Journal:  J Obstet Gynaecol India       Date:  2013-04-11

Review 2.  Investigation and management of haemorrhagic disorders in pregnancy. Haemostasis and Thrombosis Task Force.

Authors:  I D Walker; J J Walker; B T Colvin; E A Letsky; R Rivers; R Stevens
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

3.  Menstrual and obstetrical bleeding in women with inherited platelet receptor defects-A systematic review.

Authors:  Marieke C Punt; Pauline C E Schuitema; Kitty W M Bloemenkamp; Idske C L Kremer Hovinga; Karin P M van Galen
Journal:  Haemophilia       Date:  2020-01-31       Impact factor: 4.287

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.